Ampio Pharmaceuticals, Inc. (AMPE)
OTCMKTS: AMPE · Delayed Price · USD
0.310
-0.031 (-9.09%)
Apr 23, 2024, 9:30 AM EDT - Market open
Company Description
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States.
It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.
Ampio Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Michael A. Martino |
Contact Details
Address: 9800 Mount Pyramid Court, Suite 400 Englewood, Colorado 80112 United States | |
| Phone | 720-437-6500 |
| Website | ampiopharma.com |
Stock Details
| Ticker Symbol | AMPE |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001411906 |
| CUSIP Number | 03209T109 |
| ISIN Number | US03209T3077 |
| Employer ID | 26-0179592 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael A. Martino | Chief Executive Officer and Director |
| Daniel G. Stokely CPA | Chief Financial Officer, Corporate Secretary and Treasurer |
| Dr. David Bar-Or M.D. | Founder and Chairman of Scientific Advisory Board |
| April Ramirez | Clinical Trial Manager |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2024 | 15-12G | Securities registration termination |
| Apr 4, 2024 | 25 | Filing |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 25, 2024 | 8-K | Current Report |
| Mar 4, 2024 | EFFECT | Notice of Effectiveness |
| Feb 28, 2024 | 8-K | Current Report |
| Feb 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 28, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 28, 2024 | POS AM | Post-Effective amendments for registration statement |
| Feb 28, 2024 | RW | Filing |